about
Opioid receptor trafficking and interaction in nociceptorsStructural basis for bifunctional peptide recognition at human δ-opioid receptorOn the modularity of the intrinsic flexibility of the µ opioid receptor: a computational studyEvolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid PharmacophoreRole of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compoundsCoexpression of delta- and mu-opioid receptors in nociceptive sensory neurons.One-pot isomerization-cross metathesis-reduction (ICMR) synthesis of lipophilic tetrapeptidesFentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic.In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice.In vivo opioid receptor heteromerization: where do we stand?Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.Bifunctional μ/δ opioid peptides: variation of the type and length of the linker connecting the two componentsOpioid glycopeptide analgesics derived from endogenous enkephalins and endorphins14-Alkoxy- and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effectsDelta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches.Opioid Peptides: Potential for Drug Development.[Dmt1]N/OFQ(1-13)-NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist.Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.BN-9, a chimeric peptide with mixed opioid and neuropeptide FF receptor agonistic properties, produces nontolerance-forming antinociception in miceEffects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) LigandsOn the g-protein-coupled receptor heteromers and their allosteric receptor-receptor interactions in the central nervous system: focus on their role in pain modulationMolecular Pharmacology of δ-Opioid Receptors.Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice.Tolerance develops to the antiallodynic effects of the peripherally acting opioid loperamide hydrochloride in nerve-injured rats.A Cyclic Tetrapeptide ("Cyclodal") and Its Mirror-Image Isomer Are Both High-Affinity μ Opioid Receptor Antagonists.[Dmt(1)]DALDA analogues with enhanced μ opioid agonist potency and with a mixed μ/κ opioid activity profileCan amphipathic helices influence the CNS antinociceptive activity of glycopeptides related to β-endorphin?Development of a bioavailable μ opioid receptor (MOPr) agonist, δ opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance.Endomorphins: potential roles and therapeutic indications in the development of opioid peptide analgesic drugs.Interaction and regulatory functions of μ- and δ-opioid receptors in nociceptive afferent neurons.Opioid receptor targeting ligands for pain management: a review and update.Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain.The design of multitarget ligands for chronic and neuropathic pain.Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analoguesNovel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptomsModulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domainsIn Vitro Membrane Permeation Studies and in Vivo Antinociception of Glycosylated Dmt(1)-DALDA Analogues.
P2860
Q26822251-B25B9291-3001-48AE-BC03-68AE42B77289Q27644624-6BFD1B6D-4439-4B45-9237-D0A2F1724AEFQ28542919-9B6E07B5-9555-4F7A-B301-2572885FFAFDQ33747010-DC6A098B-1AF4-4148-A755-6B3C44672C40Q34054021-19480D11-C49E-4A7C-9ED3-721A0BAC50D9Q34059144-AA1A8F02-EDB6-4B45-A957-8FA1D227F57FQ34074241-5C215441-A509-4E2C-A023-CE62AE6C6AFDQ34410429-19E54F0F-2A8B-4609-AF77-0DF40A0216D0Q34559481-CA9221F9-47FB-416C-AC89-5F29971E32F2Q34702263-68536CB2-0DF3-45D0-BB6D-59F30DDB4CD5Q34939677-267B80E1-11FB-4237-ACF1-9836C7F820D7Q35621534-A87F9B81-39D8-4752-A067-83301EC20CD9Q35658766-3525011F-FAFD-40D1-BA70-F9AA63CE29CFQ35835788-81345199-9B23-41C1-9719-8B36A0D3FEFFQ36404602-AA05A9DD-82AE-495E-944D-1B3A1CEEF606Q36438816-AF0BF4A9-7F14-4FC2-8501-383F05620161Q36517233-D9A1E6C8-53DF-48D0-B8D1-C6B262FFF885Q36603205-9BA4C6A3-4B1B-46DF-BE8D-5835E147C213Q36635468-9F606A43-925C-4BA7-BF33-2C06D64B1488Q36903414-66C087E9-86DA-4D27-A70A-274017603228Q36947975-0B3F61BC-79E8-42EC-A170-27A6853DBC82Q37061890-EC271ABD-71DC-4292-9EBF-2A1EABFE2F29Q37062556-72E242DA-775C-4A30-9763-1231BAE2BF48Q37186178-DBCD4B6F-9970-4682-82A0-E70710E0E34EQ37347930-6680D26B-48B4-4D1A-A860-D5FE3823A603Q37394103-0BD1FACD-17E3-4B74-A027-64329B5C29E5Q37574675-1D8B4EC9-FA65-4A8E-AC0E-1439521F20BAQ37693264-108E6EE0-603E-416F-AEA2-D8C6F05EFB05Q37697436-2EEE6154-113A-4554-BC2B-0DB1E2D71D96Q37714225-51ADFEFA-3496-4234-A451-1F2BAC561FCAQ37834512-7BA6D494-5A5B-4139-AEF1-0A923EA95221Q37998861-839B19FC-7412-43A7-9986-BB83F9495A5AQ38028661-B5DEF133-F8D9-4942-8985-FBB26AEBCB8AQ38395503-254003D0-058C-45DF-A935-B07AA042F74CQ38664916-998094F5-B0C6-4A2C-9DED-5AEF15777A3EQ39033568-F88114DD-3268-4657-B21E-11F42DD43CB9Q39194989-433AF125-D082-48A9-BACA-C25023BEF409Q39299621-C56EB629-71F6-4493-B4A5-9A17BCB46727Q39642723-F3543E42-AB01-4AF4-9171-DF52A11423CEQ39681968-FCCBAD2C-0FCD-4B03-A44E-F612332C84F6
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Bi- or multifunctional opioid peptide drugs.
@ast
Bi- or multifunctional opioid peptide drugs.
@en
type
label
Bi- or multifunctional opioid peptide drugs.
@ast
Bi- or multifunctional opioid peptide drugs.
@en
prefLabel
Bi- or multifunctional opioid peptide drugs.
@ast
Bi- or multifunctional opioid peptide drugs.
@en
P2860
P1433
P1476
Bi- or multifunctional opioid peptide drugs.
@en
P2093
Peter W Schiller
P2860
P304
P356
10.1016/J.LFS.2009.02.025
P407
P577
2009-03-11T00:00:00Z